Biopharma solutions organization Syneos Health has acquired Kinapse, a market leading advisory and operational solutions provider to the global life sciences industry, from Hg, a specialist investor based in the U.K. Financial terms were not disclosed.

Established in 2005, Kinapse delivers services across the clinical and commercial lifecycle, and  will enhance Syneos Health’s ability to provide customers with end-to-end solutions to accelerate time to market. Kinapse’s capabilities expand Syneos Health’s regulatory, safety and pharmacovigilance consulting and operations in the post-market arena-outsourcing areas expected to experience double-digit growth. Additionally, the acquisition deepens the scale and scope of Syneos Health’s clinical trial transparency, medical writing and quality operations and consulting capabilities in the areas of R&D and clinical operations, medical affairs, market access and quality and compliance.

Kinapse works with small to mid and large biopharmaceutical companies, including many of the top 20 global biopharma companies, and has more than 600 employees across the UK, India and the U.S. The acquisition increases Syneos Health’s Asia Pacific operational and delivery capabilities and doubles the company’s consulting footprint in Europe. Kinapse operations will be integrated into Syneos Health’s consulting business, a business which drives connections between Syneos Health’s core clinical and commercial offerings to optimize product launch and commercialization results.

“As customers increasingly face risk, competition and rising development costs, the innovative, technology-enabled solutions provided by Kinapse are seeing increasing demand,” said Alistair Macdonald, chief executive officer, Syneos Health. “Through this combination we continue to inject new and enriched high-value solutions into the industry’s only end-to-end offering, unlocking value for all of our biopharmaceutical customers. Additionally, with Kinapse’s growth, recurring revenue streams and new cross-selling opportunities, we’re poised to further strengthen our commercial business by integrating their services into more comprehensive offerings.”

Dawn Marriott-Sims, executive chairman, Kinapse, said, “We’ve been following Syneos Health as the company has forged a new model for accelerating therapies to market, and we look forward to adding further depth to its end-to-end offering. We see growth opportunities driven by the integration of our solutions and the ability to tap into Syneos Health’s broad customer base.”

Mr. Macdonald added, “This combination is an ideal strategic and cultural fit. We welcome the Kinapse team to the Syneos Health family and look forward to bringing more innovative services to our customers.”